Tag: myelodysplastic syndromes

Kurome Therapeutics advances with FDA-approved IND for KME-0584 in AML and HR MDS clinical trial

businessnewstoday- February 17, 2024

In a significant development for cancer research, Kurome Therapeutics Inc. has announced the U.S. Food and Drug Administration (FDA) clearance of the Investigational New Drug ... Read More

Gilead Sciences discontinues Phase 3 ENHANCE Study on higher-risk MDS due to futility

businessnewstoday- July 22, 2023

Biopharmaceutical firm Gilead Sciences (Nasdaq: GILD) has announced the termination of its Phase 3 ENHANCE study in higher-risk myelodysplastic syndromes (MDS) due to a lack ... Read More

Zydus Lifesciences launches Revlimid generic – Lenalidomide Capsules in US

pallavi123- September 20, 2022

Indian pharma company Zydus Lifesciences Limited, previously known as Cadila Healthcare Limited has launched Lenalidomide Capsules, a generic of Revlimid, in the US market. The ... Read More

Medac resubmits treosulfan NDA to FDA, says Medexus Pharmaceuticals

pallavi123- July 30, 2022

Medexus Pharmaceuticals said that its strategic partner medac has resubmitted the new drug application (NDA) for treosulfan with the US Food and Drug Administration (FDA). ... Read More

Sun Pharma to settle patent litigation with Celgene for generic Revlimid

pallavi123- June 22, 2021

Sun Pharmaceutical Industries (Sun Pharma) along with one of its fully-owned subsidiaries has reached an agreement with Celgene, a fully-owned subsidiary of Bristol Myers Squibb, ... Read More

Natco Pharma gets FDA approval for Lenalidomide Capsules

pallavi123- May 24, 2021

Natco Pharma has secured the final approval from the US Food and Drug Administration (FDA) of its abbreviated new drug application (ANDA) for Lenalidomide Capsules, ... Read More

Curis doses first patient in CA-4948 phase 1 clinical trial in AML and MDS

pharmanewsdaily- July 7, 2020

CA-4948 phase 1 clinical trial : US biotech company Curis said that it has dosed the first patient with CA-4948 in a phase 1 clinical ... Read More

EC approves Reblozyl for transfusion-dependent anemia in adults

pharmanewsdaily- June 28, 2020

Bristol Myers Squibb and Acceleron Pharma have secured approval from the European Commission (EC) for their jointly developed erythroid maturation agent Reblozyl (luspatercept) for the ... Read More